FDA authorised the first mRNA vaccine in December 2020

The signal

On 11 December 2020, the FDA issued an Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine, a health-science milestone: the first authorisation in the United States for a vaccine built on messenger RNA technology, for use in people 16 and older. FDA's own archived EUA tracker records the authorisation as “12/11/2020 (issued)” and separately records it as revoked on 27 August 2025.

The evidence

FDA's own consolidated letter of authorization, reissued 22 August 2024, states plainly: “On December 11, 2020, the Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for emergency use of Pfizer-BioNTech COVID19 Vaccine (Original monovalent)... for individuals 16 years of age and older,” and lists reissuance dates of 23 December 2020, 25 February 2021, 10 May 2021, 25 June 2021 and 12 August 2021, each revising specific technical or reporting details. On 23 August 2021, FDA fully approved the same vaccine under the brand Comirnaty and reissued the letter to cover both. Separately, the Nobel Prize press release of 2 October 2023 credits Katalin Karikó and Drew Weissman's discoveries on nucleoside base modifications as work that “were critical for developing effective mRNA vaccines against COVID-19” and “contributed to the unprecedented rate of vaccine development.” That is an outside, expert-panel recognition of the underlying science, not a claim by FDA or the vaccine's manufacturers.

Timeframe and confidence

Confidence in the authorisation date and its reissuance chain is high, since both FDA's own tracker and its consolidated letter independently record the same 11 December 2020 date. An editorial point worth separating: a single authorised product reaching the public quickly is evidence the mRNA platform can be deployed fast for one target under emergency conditions, and the Nobel citation validates the underlying chemistry, but neither establishes on its own that the platform will be similarly fast against a different, future pathogen.

What would change the reading

Authorisation of a second, unrelated mRNA vaccine against a novel pathogen on a comparably short timeline, opened and cited directly, would generalise the “fast platform” reading beyond this one case. The original EUA's own revocation, recorded by FDA as of 27 August 2025, is worth distinguishing from a safety failure: it followed the vaccine's earlier full approval as Comirnaty, and this piece has not opened a document establishing a different reason.

• Has a second mRNA vaccine against an unrelated pathogen reached authorisation on a similarly short timeline since 2020?
• What does FDA's revocation record for the original EUA state as the reason, beyond the fact of Comirnaty's full approval?
• Does the Nobel Committee's 2023 citation change how regulators evaluate future mRNA submissions, or only how the science is credited?

The documented chain, one EUA issued in December 2020, revised six times, superseded by full approval in August 2021, and revoked in 2025, shows an authorisation is a living document under continuous revision, not a single fixed event.

Source trail

1. Emergency Use Authorization Archived Information (Pfizer-BioNTech COVID-19 Vaccine entry)www.fda.gov · Source publication: not established · Retrieved 2026-09-16

   FDA's own archive records the vaccine's EUA as issued 12/11/2020 and revoked 27 August 2025, as retrieved 16 September 2026.

2. Reissued Letter of Authorization, Pfizer-BioNTech COVID-19 Vaccinewww.fda.gov · Source publication: 2024-08-22 · Retrieved 2026-09-16

   Consolidated authorization letter documenting the original 11 December 2020 EUA and every reissuance date through 2021 full approval.

3. Press release: The Nobel Prize in Physiology or Medicine 2023www.nobelprize.org · Source publication: 2023-10-02 · Retrieved 2026-09-16

   Nobel Committee's framing of the nucleoside-base-modification discoveries as enabling the mRNA vaccines' rapid development.

Read across the evidence

• A 2021 approval opened a weight-management use for semaglutide
• WHO's pandemic statement became a cross-sector reference date
• Medicare telehealth visits jumped from under 1% to near half

Governance & change · All 100 historical records